Welcome to our dedicated page for Amphastar Pharma SEC filings (Ticker: AMPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the exact moment Amphastar Pharmaceuticals discloses an FDA manufacturing observation or a change in its insulin API strategy can feel like hunting for a needle in a 300-page haystack. Because every cGMP deviation, pipeline update, and recall risk must be reported, AMPH’s SEC documents are dense with technical language that even seasoned analysts find daunting.
Stock Titan solves that problem by pairing real-time EDGAR feeds with AI-powered summaries that translate each filing into plain English. Want the highlights of an Amphastar Pharmaceuticals annual report 10-K simplified? Our platform extracts segment revenues, R&D spend, and key FDA milestones in seconds. Need the latest Amphastar Pharmaceuticals quarterly earnings report 10-Q filing? It arrives with instant ratios and trend graphs. Form 8-K material events—such as trial results or supply-chain contracts—are pushed to you with Amphastar Pharmaceuticals 8-K material events explained so you never miss a market-moving update.
For governance insights, track Amphastar Pharmaceuticals insider trading Form 4 transactions the moment executives file; our alerts surface patterns in Amphastar Pharmaceuticals executive stock transactions Form 4. Dig into the proxy for Amphastar Pharmaceuticals proxy statement executive compensation or explore Amphastar Pharmaceuticals earnings report filing analysis to compare margin shifts. Whether you’re understanding Amphastar Pharmaceuticals SEC documents with AI for compliance checks or evaluating competitive position, Stock Titan’s coverage of every 10-K, 10-Q, 8-K, S-1, and real-time Amphastar Pharmaceuticals Form 4 insider transactions gives you the clarity and speed required to make informed decisions.
Amphastar Pharmaceuticals entered a Distribution Agreement effective October 21, 2025 with Nanjing Chengong Pharmaceutical to expand sales of BAQSIMI nasal powder across Mainland China, Taiwan, Hong Kong, and Macau. Amphastar appointed Chengong as the exclusive distributor in the Greater China region. Chengong will obtain regulatory approvals and conduct required post‑marketing clinical trials.
The agreement includes minimum purchase amounts per contract year and a profit‑sharing structure on earnings above a floor price per unit, determined using Chengong’s per‑unit net revenue. The term is 10 years, with both parties holding termination rights without cause after the fourth Contract Year. Payments will be in U.S. dollars, and total revenue over the term is not determinable based on the filing. The transaction is a related party arrangement: executives and certain family members beneficially own a majority of Hanxin, Chengong’s parent. The Company’s independent and disinterested Audit Committee members evaluated and approved the agreement.
Floyd F. Petersen, a director of Amphastar Pharmaceuticals, Inc. (AMPH), sold 500 shares of the company's common stock on 10/01/2025 at a weighted-average price of $27.2048 per share. The sale was made under a pre-established Rule 10b5-1 trading plan adopted on 11/26/2024. After the reported sale, Mr. Petersen beneficially owned 76,031 shares, held directly. The Form 4 was signed on behalf of the reporting person by Eva Wen as power of attorney on 10/02/2025. The registrant will provide, upon request, details on the number of shares sold at each execution price within the reported range of $26.74 to $27.39.
Insider sale notice for AMPH: This Form 144 shows a proposed sale of 500 shares of Amphastar Pharmaceuticals common stock through UBS Financial Services on or about 10/01/2025, with an aggregate market value listed as $13,370.00. The shares were originally acquired as RSUs on 06/07/2022. The filer previously sold three blocks of 500 shares each during July, August and September 2025, generating gross proceeds of $11,733.95, $10,415.75, and $15,491.65 respectively. The filing lists total shares outstanding as 46,495,077, indicating the planned sale is a small fraction of the company’s outstanding shares. The notice includes the signer’s representation that no undisclosed material adverse information about the issuer is known.
Floyd F. Petersen, a director of Amphastar Pharmaceuticals (AMPH), sold 500 shares on 09/02/2025 under a pre-existing Rule 10b5-1 trading plan. The sales were executed at a weighted-average price of $30.9833 per share, with individual sale prices ranging from $30.60 to $31.225. Following the reported disposition, Petersen is recorded as beneficially owning 76,531 shares. The Form 4 was signed by Eva Wen by power of attorney on 09/03/2025.
Form 144 notice by Floyd Peterson for Amphastar Pharmaceuticals, Inc. (AMPH). The filer notifies a proposed sale of 500 shares of common stock through UBS Financial Services on NASDAQ with an approximate sale date of 09/02/2025 and an aggregate market value listed at $15,450.00. The shares were acquired as RSUs on 06/07/2022. The filing also discloses three sales by the same person in the past three months totaling 1,500 shares on 06/02/2025, 07/02/2025 and 08/01/2025 with combined gross proceeds of $34,984.75. The form includes the required representation that the seller is not aware of undisclosed material adverse information.
Amphastar Pharmaceuticals entered a license agreement with Nanjing Anji Biotechnology granting Amphastar exclusive rights in the United States and Canada to develop, make, use and commercialize products incorporating certain compounds, including three identified Licensed Products. Amphastar paid an $0.75 million earnest payment and a $5.25 million upfront fee on signing and agreed to up to $42 million in development milestones and up to $225 million in sales milestones, plus royalty payments capped at $22.5 million per product per year and a $60 million accumulated cap per product. Amphastar will share a percentage of sublicense income with Anji, and Anji will pay Amphastar royalties on net sales tied to Amphastar-licensed patents outside the Territory.
The agreement term runs product-by-product and region-by-region to the tenth anniversary of first commercial sale with an Amphastar option to extend up to ten additional years or until patent claims lapse. The company disclosed customary forward-looking statements and identified risks including regulatory approval, commercialization success, legal and regulatory changes, and supply-chain disruptions, and incorporated the full Agreement by reference to be filed as an exhibit.
Amphastar Pharmaceuticals (AMPH) – SEC Form 4
Director Floyd F. Petersen disclosed the sale of 500 common shares on 01 Aug 2025 at a weighted-average price of $20.8315. The transaction was executed under a Rule 10b5-1 trading plan adopted 26 Nov 2024, indicating it was pre-scheduled rather than discretionary. After the sale, Petersen directly owns 77,031 shares, so the disposition equals roughly 0.6 % of his stake and is immaterial relative to Amphastar’s total share count. No derivative securities activity or additional insider trades were reported.
The filing therefore conveys routine insider diversification without signaling a change in corporate fundamentals or outlook.
FAQ
What is the current stock price of Amphastar Pharma (AMPH)?
What is the market cap of Amphastar Pharma (AMPH)?
